TNF Inhibitors Market (Drug - Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab; Application - Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global TNF Inhibitors market size was estimated at USD 4.2 billion in 2021 and is expected to surpass around USD 20.4 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.2 during the forecast period 2022 to 2030.

The rise in global occurrence of autoimmune illnesses such as Psoriasis, Inflammatory Bowel Disorder, Rheumatoid Arthritis (RA), and Crohn's disease, as well as the rise in the elderly populace, are the primary reasons likely to drive the expansion of the global TNF inhibitors market.

Golimumab, Etanercept, Certolizumab, Infliximab, and Adalimumab are TNF inhibitors utilized to address inflammatory illnesses such as inflammatory bowel disease and psoriasis. Manufacturers in the global TNF inhibitors market are likely to provide a wide range of medications to treat a variety of inflammatory illnesses. During the COVID-19 pandemic, however, a research found that if a patient was completely vaccinated with the Pfizer vaccine and was taking a TNF inhibitor, the patient's antibody response to the virus that caused COVID-19 was diminished. A third injection of the vaccine, according to the study, is likely to boost antibody levels in the body.

The global TNF inhibitors market is relatively competitive, with many prominent competitors. In terms of market share, a few major competitors currently dominate the industry. Some major players are purchasing other businesses in order to strengthen their global market positions, whilst others are developing new items. With the clearance of the US Food and Drug Administration (FDA) in December 2019, Amgen added another blockbuster medicine, AVSOLA (infliximab-axxq), to its current portfolio of biosimilar drugs. As of the reference product, Remicade (infliximab), the AVSOLA has been authorized for all indications of chronic inflammatory diseases, which is projected to boost the global TNF inhibitors market in the years to come.

Report Scope of the TNF Inhibitors Market

Presence of Advanced Healthcare Facilities and Favorable Policies to Drive Demand in the Market

The world's population is aging rapidly, particularly in developed countries, such as the U.S., Japan, and Western Europe. In comparison to developing countries, developed countries have higher rate of aging. This can be linked to these nations' steadily growing health infrastructure, reimbursement systems, and advancements in health-care facilities. In addition to that, availability to numerous TNF inhibitors has increased, particularly in developed nations. As a result, the people's life expectancy has grown. The senior population is a big fan of TNF inhibitors since they help them live longer and better lives. An increase in the number of aged individuals leads to a higher risk of illness, which is anticipated to drive up demand in the global TNF inhibitors in the years to come.

High Prevalence of Rheumatoid Arthritis to Spell Growth for the Market

The US Food and Drug Administration authorized adalimumab, often known as Humira, as the first and only entirely human monoclonal antibody for the treatment of rheumatoid arthritis. Humira, AbbVie's largest medication, was released in 2003 and has consistently generated the most revenue for the firm, which is likely to fuel expansion of the global TNF inhibitors market in the years to come.

Due to its widespread prevalence, rheumatoid arthritis is likely to account for substantial chunk of the global TNF inhibitors market. Furthermore, rheumatoid arthritis is more common in women than in men, is predicted to account for around two-thirds of the entire patient population with arthritis, and it worsens with age, all of which are expected to move the global TNF inhibitors market forward.

Hospital pharmacies are predicted to acquire one of the leading market shares by owing to the availability of physicians and treatment in one single location. Additionally, biosimilars producers want to control the availability of their goods to as many hospitals and patients as possible in order to fulfill their increasing requirements, which is expected to fuel the segment's growth and contribute to its part of global market revenue.

Growing Prevalence of TNF Inhibitor Biosimilars is Expected to Support Market Expansion

Most of the major TNF inhibitors, such as remicade, Enbrel, and humira, have lost their patents in the recent years, and more TNF inhibitors are anticipated to lose their patents soon. As a result of patient affordability in low-income countries and increasing patient awareness, TNF inhibitor biosimilars are expected to acquire market share throughout the projection period. In 2022, the patent on humira (adalimumab), the world's most popular medication, expired. In 2014, Johnson & Johnson's remicade lost its patent. TNF inhibitor biosimilars are projected to open up profitable potential in low-income nations by making TNF inhibitors more accessible and inexpensive, which will likely increase TNF inhibitor usage. This, in turn, is expected to fuel the demand for TNF inhibitors. Furthermore, a robust clinical pipeline of TNF inhibitors biosimilars is anticipated to bolster growth of the global TNF inhibitors market.

North America and Europe to Lead the Market due to the Presence of Huge Ageing Population Base

North America is likely to lead the global TNF inhibitors market during the forecast period. The region's prominence is attributed to a number of factors, including well-established direct reimbursement regulations and the presence of superior healthcare infrastructure. Due to the USFDA's fast medication approval effort, which supported market expansion in this region, the US is likely to account for a substantial chunk of the market in the years to come.

Following North America, Europe is likely to account for the second-largest market for TNF inhibitors, driven by growing demand from the regional aging population and rising healthcare costs. Huge expenditures by leading players, as well as continued expansion in R&D efforts in the area, are likely to contribute significantly to market revenue during the forecast period.

Asia Pacific is expected to expand at a rapid growth rate, owing to the large patient populations in China and India for disorders including Crohn's disease, IBD, and psoriasis. Furthermore, an expansion in the role of the government in assisting the healthcare industry, as well as continuous research activities in the region, is likely to boost market growth in the region.

Some of the prominent players in the TNF Inhibitors Market include:

AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., UCB Inc., Samsung Bioepis, Biogen, Merck & Co., Takeda Pharmaceutical Company, Pfizer, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global TNF Inhibitors market

By Drug

• Adalimumab
• Certolizumab
• Etanercept
• Golimumab
• Infliximab

By Application

• Rheumatoid Arthritis
• Psoriasis
• Inflammatory Bowel Disease
• Ankylosing Spondylitis
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Regional Outlook

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global TNF Inhibitors industry analysis from 2022 to 2030 to identify the prevailing TNF Inhibitors industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global TNF Inhibitors industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global TNF Inhibitors industry trends, key players, market segments, application areas, and market growth strategies.